SecBot SecBot
8-K ·Filed Feb 24, 2026

DAWN

Day One Biopharmaceuticals, Inc.
BULLISH
Impact 8/10
Horizonmonths Processed8mo ago SEC0001193125-26-066926
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The significant revenue growth, decreasing R&D expenses, and strong guidance reaffirmation suggest the company is successfully commercializing OJEMDA. Traders should monitor prescription growth trends and upcoming clinical data readouts in 2026 as potential catalysts.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+20
Entry
$10.92
T+0 close · Feb 24, 2026 · via day close
Latest settled
+95.79%
T+20 · $21.37
Vs SPY
+101.02%
α at T+20
Next horizon
T+60
due 6mo ago
  1. T+0 · Feb 25 $10.92entry
  2. T+1 · 9mo ago −2.43%α −1.88% · $10.65
  3. T+5 · 9mo ago +17.91%α +19.01% · $12.87
  4. T+20 · 8mo ago +95.79%α +101.02% · $21.37
  5. T+60 · due 6mo ago Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Day One Biopharmaceuticals reported strong 2025 financial results with OJEMDA net product revenue of $155.4 million, representing 172% year-over-year growth. The company reaffirmed its 2026 U.S. net product revenue guidance of $225-$250 million, reflecting continued commercial momentum. R&D expenses decreased significantly year-over-year while prescription volume grew 181%, indicating strong market adoption.

Key Financial Metrics

Revenue
$155.4M
+172.0% YoY
EPS
$-1.04
Guidance
$225M-$250M
maintained

Key Facts

  • OJEMDA net product revenue was $155.4 million for full year 2025, up 172% year-over-year
  • Fourth quarter 2025 revenue was $52.8 million
  • Total prescriptions in 2025 were 4,635, representing 181% growth versus 2024
  • Company reaffirmed 2026 U.S. net product revenue guidance of $225-$250 million
  • R&D expenses decreased to $148.1 million in 2025 from $227.7 million in 2024
  • Cash position was $441.1 million as of December 31, 2025

Financial Impact

Revenue growth of 172% YoY with $155.4 million in net product revenue for 2025

revenuer&dcash

Segment Breakdown

SegmentRevenueGrowth
OJEMDA$155.4M+172.0%

Risk Factors

  • Biotech stock volatility
  • Dependence on single product (OJEMDA) for revenue
  • Regulatory risks for ongoing and future trials

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 8 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-066926
Document: dawn-20260224.htm0001193125-26-066926
Document: dawn-ex99_3.htm0001193125-26-066926
Document: dawn-ex99_2.htm0001193125-26-066926
Document: 0001193125-26-066926-index-headers.html0001193125-26-066926
Document: 0001193125-26-066926-index.html0001193125-26-066926
Document: 0001193125-26-066926.txt0001193125-26-066926
CONTEXT: Previous Earnings (2026-02-24)0001193125-26-066926

Track record

6 reports on DAWN

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. May 4, 202628w ago 15-12G Neutral 5/10 No price data
  2. Apr 23, 202629w ago 25-NSE Neutral 9/10 Entry $21.53 No price data
  3. Apr 23, 202629w ago 8-K Neutral 9/10 Entry $21.53 No price data
  4. Apr 17, 202630w ago 10-K/A Neutral 4/10 Entry $21.48 No price data
  5. Mar 6, 202636w ago Press Release Bullish 9/10 Entry $21.20 to $21.46 ▲ +1.23% +3.27% vs SPY
  6. Feb 24, 202637w ago 8-K Bullish 8/10 Viewing Entry $10.92 to $21.37 ▲ +95.79% +101.02% vs SPY
Showing 6 of 6

US Market Status

Market Closed · Opens in 6h 1m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Feb 24, 2026